Slide 1: Positive final Phase 2a data confirms amsulostat's competitive profile in myelofibrosis
For personal use only ™ Positive final Phase 2a data confirms amsulostat’s competitive profile in myelofibrosis Gary Phillips, CEO 30th September 2025
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Investment Highlights
Investment Highlights For personal use only Australian-founded clinical Clinical Backed by specialist Focus on first-in-class and Funded into 2027 with near stage drug developer. stage drug developer. healthcare investors – best-in-class drugs backed term data to drive value 47% institutional. by in
Slide 4: Shareholders & Cash
Shareholders & Cash Financial Information (ASX: SNT) Share Price & Volume - YTD For personal use only Share price – 29 September 2025 $0.024 Close 0.1 Market cap A$39.2m 0.09 0.08 0.07 Proforma cash balance (30 Jun 2025)1 A$20.7m 0.06 0.05 Enterprise value A$18.5m 0.04 0.03 Note 1: 0.02 Proforma cas
Slide 5: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells For personal use only Myelofibrosis is characterised by a build up of scar tissue (fibrosis) Key Facts in bone marrow and abnormal proliferation of blood precursor cells, reducing the production
Slide 6: Limited treatment options currently
Myelofibrosis Limited treatment options currently For personal use only Current standard of care (SoC): JAK inhibitors Amsulostat Key• Class Factsof drugs used in the management of splenomegaly In contrast to SoC, amsulostat intervenes at the source, (enlarged spleen) and other constitutional sympto
Slide 7: Lysyl Oxidases in Myelofibrosis
Lysyl Oxidases in Myelofibrosis Amsulostat designed to improve the bone marrow microenvironment ▪ Lysyl oxidase gene family upregulated in the bone marrow (BM) of myelofibrosis patients; For personal use only increased lysyl oxidase activity adversely impacts BM health in several ways* Structural ef
Slide 8: Lysyl Oxidases in Myelofibrosis: amsulostat mode of action
Lysyl Oxidases in Myelofibrosis Amsulostat designed to improve the bone marrow microenvironment ▪ Lysyl oxidase gene family upregulated in the bone marrow (BM) of myelofibrosis patients; For personal use only increased lysyl oxidase activity adversely impacts BM health in several ways* Pan-LOX inhib
Slide 9: Aims/Methods
Aims/Methods MF-101 add-on to RUX (NCT4676529) ▪ This add-on phase aimed to further evaluate the safety and efficacy of amsulostat For personal use only (200 mg BID) in patients with MF on stable background regimens of ruxolitinib (RUX) over a 52-week period STUDY POPULATION DESIGN ENDPOINTS PRIMARY
Slide 10: Baseline Characteristics
Baseline Characteristics Heterogenous population with a high disease burden For personal use only ▪ Study now complete Characteristic N=16 ▪ 13 patients (pts) reached 12 weeks Age, median (range), years 71 (46-82) Sex, male, n (%) 7 (44) ▪ 11 pts reached 24 weeks Time since MF diagnosis, median (ran
Slide 11: Total Symptom Score
Total Symptom Score 73% (8/11) of patients achieved TSS50 at Week 24 or beyond Reduction at W24 Additional reduction past W24 For personal use only ▪ Symptom relief continues for * Pt continued past W38 # Pt completed W52 and study patients: TSS Change from Baseline (%) Baseline TSS ▪ 73% (8/11) pat
Slide 12: Spleen Volume Reduction
Spleen Volume Reduction 44% (4/9) of patients achieved SVR25 at Week 24 or beyond Reduction at W24 For personal use only Additional reduction past W24 ▪ Improved spleen volume reduction: * Pt continued past W38 # Pt completed W52 and study ▪ At Week 24, 7/9 (78%) evaluable 20 Baseline Spleen Volume
Slide 13: Positive top line Phase 2a data highlights amsulostat's potential in myelofibrosis
Positive top line Phase 2a data highlights amsulostat’s potential in myelofibrosis For personal use only ▪ Improvements of 50% or more in total symptom score (TSS50) were observed quickly (as early as 12 weeks) and were sustained, with 73% (8/11) of patients achieving TSS50 at Week 24 or beyond ▪ Me
Slide 14: Syntara appoints global myelofibrosis experts to support amsulostat development
Syntara appoints global myelofibrosis experts to support amsulostat development For personal use only Strategic Advisors to Syntara Board, Haematology ▪ Dr Adam Craig Former CEO of CTI BioPharma Corp, responsible for taking the JAK inhibitor Vonjo (pacritinib) through clinical development, FDA appro
Slide 15: Strong interest in MF assets from strategics
Strong interest in MF assets from strategics Target / Acquiror / / / / For personal use only Date of Announcement Dec-2024 Feb-2024 June-2023 July-2022 Drug Name Elritercept Pelabresib Pacritinib Momelotinib Lead Indication / MDS and MF Myelofibrosis Myelofibrosis Myelofibrosis Phase (at transaction
Slide 16: Poised To Deliver Near Term Value
Poised To Deliver Near Term Value For personal use only Phase 1 Funding and Target Drug Indication Preclinical Phase 2 Milestone(s) Healthy Clinical Partners Patients participants FDA approved development plan and Myelofibrosis partner engagement H1 2026 Amsulostat Interim Data Pan-LOX High Risk MDS
Slide 17: Recent & Anticipated News Flow
Recent & Anticipated News Flow Strong and growing pipeline with advancement in studies expected to provide value inflection points For personal use only June 2025 Mid 2025 Mid 2025 Q3 2025 Q4 2025 • FDA grants Fast Track Amsulostat Phase SNT-9465 Phase 1a/b • FDA feedback on Amsulostat Phase 1c/2a D
Slide 18: For personal use only
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au www.syntaraTX.com.au